November 24, 2016 - By Michael Collier
In analysts report shared with investors on 24 November, Exova Group (LON:EXO) stock “Outperform” was reaffirmed by Analysts at Credit Suisse. They currently have a GBX 220.00 PT on the stock. Credit Suisse’s PT would suggest a potential upside of 11.53% from the company’s current price.
Out of 6 analysts covering Exova Group Plc (LON:EXO), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 225 is the highest target while GBX 158 is the lowest. The GBX 208 average target is 5.45% above today’s (GBX 197.25) stock price. Exova Group Plc has been the topic of 23 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Barclays Capital maintained Exova Group Plc (LON:EXO) rating on Friday, February 5. Barclays Capital has “Overweight” rating and GBX 195 price target. The stock of Exova Group Plc (LON:EXO) earned “Add” rating by Peel Hunt on Wednesday, September 21. As per Friday, March 4, the company rating was maintained by Barclays Capital. The stock of Exova Group Plc (LON:EXO) earned “Buy” rating by Shore Capital on Tuesday, February 23. The stock of Exova Group Plc (LON:EXO) earned “Overweight” rating by Barclays Capital on Monday, September 14. The firm has “Outperform” rating given on Wednesday, November 11 by Credit Suisse. The stock has “Hold” rating given by Peel Hunt on Friday, January 15. Investec maintained Exova Group Plc (LON:EXO) rating on Thursday, February 11. Investec has “Buy” rating and GBX 190 price target. The stock has “Outperform” rating given by Credit Suisse on Wednesday, March 23. Barclays Capital maintained the shares of EXO in a report on Monday, August 24 with “Overweight” rating.
The stock increased 1.15% or GBX 2.25 on November 24, hitting GBX 197.25. About 5,774 shares traded hands. Exova Group Plc (LON:EXO) has risen 20.37% since April 26, 2016 and is uptrending. It has outperformed by 14.96% the S&P500.
Exova Group plc is a United Kingdom well-known provider of testing and advisory services. The company has a market cap of 500.85 million GBP. The Firm is a laboratory testing firm operating approximately 140 laboratories and offices in over 30 countries throughout Europe, the Americas, the Middle East and Asia/Asia Pacific. It has a 24.17 P/E ratio. The Company’s divisions include Europe, Americas and Rest of World.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.